(NYSE: MRK) Merck & Co's forecast annual revenue growth rate of 5.3% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.6%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.81%.
Merck & Co's revenue in 2026 is $64,235,000,000.On average, 29 Wall Street analysts forecast MRK's revenue for 2026 to be $169,460,088,645,400, with the lowest MRK revenue forecast at $157,598,502,945,856, and the highest MRK revenue forecast at $179,556,956,321,848. On average, 24 Wall Street analysts forecast MRK's revenue for 2027 to be $178,452,456,293,328, with the lowest MRK revenue forecast at $166,285,581,821,856, and the highest MRK revenue forecast at $193,793,837,588,344.
In 2028, MRK is forecast to generate $185,578,342,994,184 in revenue, with the lowest revenue forecast at $164,297,481,770,520 and the highest revenue forecast at $202,607,499,613,680.